Erratum: FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study

J Clin Oncol. 2023 Sep 12:JCO2301858. doi: 10.1200/JCO.23.01858. Online ahead of print.NO ABSTRACTPMID:37699171 | DOI:10.1200/JCO.23.01858
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Source Type: research